International Business Machines Corp vs Neurocrine Biosciences Inc — how do they compare? International Business Machines Corp trades at $237.59 (market cap $222.64B), while Neurocrine Biosciences Inc trades at $159 (market cap $16.76B). The key difference: International Business Machines Corp is far larger — about 13.3× Neurocrine Biosciences Inc's market cap, and International Business Machines Corp pays a 2.86% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| IBM | NBIX | |
|---|---|---|
Market Cap | $222.64B | $16.76B |
Volume | 4,481,527 | — |
Sector | Technology | Health |
52-Week High | $329.23 | $185.50 |
52-Week Low | $205.77 | $123.10 |
Enterprise Value | $279.78B | $16.78B |
Dividend Yield | 2.86% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Trailing returns across standard periods
Latest headlines on both assets
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →